Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesEfficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromesWorld health dilemmas: Orphan and rare diseases, orphan drugs and orphan patientsThe oral iron chelator deferiprone protects against iron overload-induced retinal degenerationClinically approved iron chelators influence zebrafish mortality, hatching morphology and cardiac function.Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.Systemic administration of the iron chelator deferiprone protects against light-induced photoreceptor degeneration in the mouse retinaHow does the macula protect itself from oxidative stress?New developments and controversies in iron metabolism and iron chelation therapy.Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Zinc acquisition: a key aspect in Aspergillus fumigatus virulence.Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.Targeting zinc homeostasis to combat Aspergillus fumigatus infections.Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.Iron chelator alleviates tubulointerstitial fibrosis in diabetic nephropathy rats by inhibiting the expression of tenascinC and other correlation factors.Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.The proceedings of the 19Th international conference on chelation held in London, United Kingdom: major changes in iron chelation therapy in the last 25 years using deferiprone (L1) has resulted in the complete treatment of iron overload.Management of cardiac hemochromatosis.
P2860
Q24289511-E67A5258-9FCC-4A8B-A6E8-6F9B2C22C1C8Q26764818-5092F78C-7601-4A8A-AA4F-73CC91C546EFQ26826936-29829C8E-F962-4D5E-A33A-ABE23100820CQ34281402-3D3109BD-5AB4-400B-BB82-793B19B9A359Q34351633-48297F06-BAA9-4C6D-8201-F7644814A2E1Q34761250-B892E99D-73B2-443B-A3B4-BA3E343D0C33Q36050418-3BE8E1E9-42BC-453F-B194-6F19315DB292Q36083959-C049CE82-D72F-4DB9-9B15-5CED562E6186Q36719376-C2C929F6-83BA-4E53-B8F2-AFBBBD01626EQ37765561-B30B4677-B14F-4E82-B6E0-341061C00E61Q37947588-A5D89D03-E9A4-4ED1-8261-547AEB2EA4A6Q38099045-05B3C8EF-1CE0-4120-8BE1-08DD18F88FD0Q38221674-20C3DA15-2EC7-4CE2-BBDF-2D9DABB03F4FQ39866692-4A80CF2C-53B4-4FE5-8428-5EFA1F9BF399Q41429682-8EFAF868-57DB-40F7-BD74-87D0A81CC1A6Q43044197-C078C6A6-F585-4C41-8210-5CE324D6B6F9Q48665941-48FE35C0-B365-4545-AB10-D856D4A70CA5Q51343677-6DA9966E-7240-4C46-86BB-64BE728492A0Q53153270-06437A9F-4978-4067-B3FC-106D03F14ACFQ53153275-5FFD3A18-B253-45C4-A9D7-EC27158B6010Q55230811-E595147D-BC84-4881-9F57-F7FAD6440D82
P2860
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Safety issues of iron chelatio ...... renal and infectious diseases.
@en
Safety issues of iron chelatio ...... renal and infectious diseases.
@nl
type
label
Safety issues of iron chelatio ...... renal and infectious diseases.
@en
Safety issues of iron chelatio ...... renal and infectious diseases.
@nl
prefLabel
Safety issues of iron chelatio ...... renal and infectious diseases.
@en
Safety issues of iron chelatio ...... renal and infectious diseases.
@nl
P2093
P2860
P1476
Safety issues of iron chelatio ...... renal and infectious diseases.
@en
P2093
A Aessopos
A Kolnagou
G J Kontoghiorghes
P2860
P304
P356
10.1517/14740330903535845
P407
P577
2010-03-01T00:00:00Z